Wockhardt’s Zaynich® (Zidebactam/Cefepime, WCK 5222) achieves highest – ever efficacy meeting superiority in a global, pivotal, registration – enabling Phase III study in complicated urinary tract infection (cUTI) achieving 96.8% clinical cure rate
Zaynich® (Zidebactam/Cefepime, WCK 5222) achieves over 97% Efficacy in Clinical Study for serious infections caused by Meropenem – Resistant Gram – Negative Pathogens
Zaynich® (Zidebactam/Cefepime, WCK 5222) achieves over 97% Efficacy in Clinical Study for serious infections caused by Meropenem – Resistant Gram – Negative Pathogens
Indian Drug Regulator Approves Wockhardt’s New Generation Oral Antibiotic Miqnaf® (Nafithromycin) for the Treatment of Community – Acquired Bacterial Pneumonia (CABP)
Indian Drug Regulator Approves Wockhardt’s New Generation Oral Antibiotic Miqnaf® (Nafithromycin) for the Treatment of Community – Acquired Bacterial Pneumonia (CABP)
Zaynich™ (Zidebactam/Cefepime, WCK 5222) enables US cancer patient undergo successful liver transplant and resume chemotherapy by eradicating dual extreme – drug resistant Gram negative pathogens
